ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Company to willingly delist from the Toronto Stock Exchange (TSX) Last trading day on TSX will be July 21, 2023 ProMIS signed up with the Nasdaq Capital Market LLC on July 7, 2022, and it has actually considering that ended up being the main market based upon trading volume. The Company thinks that this combination to the Nasdaq will help with the chance to carry out deals in accordance with the guidelines of Nasdaq as its main market while producing a main market for typical shares and supplying adequate liquidity. The Company likewise thinks that delisting from the TSX will reduce the expenditures of a double listing and supply cost savings in time and effort of management, which can be rerouted to efforts meant to produce investor worth. In accordance with the requirements of the TSX Company Manual, investor approval is not needed in regard of the voluntary delisting from the TSX as the Company’s typical shares are noted on Nasdaq, which is an appropriate alternative market for the noted securities. The majority of brokers in Canada, consisting of discount rate and online brokers, have the capability to purchase and offer securities noted on Nasdaq. The Company’s Nasdaq listing will continue to offer investors with availability to trade the Company’s typical shares. The worth of financier shares or warrants is not associated with or depending on the listing. Investors holding shares or warrants in Canadian brokerage accounts must call their brokers to validate how to trade the Company’s shares on Nasdaq. Investors might likewise call the Company at info@promisneurosciences.com for support. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is an advancement phase biotechnology business concentrated on creating and establishing antibody rehabs selectively targeting poisonous misfolded proteins in neurodegenerative illness such as Alzheimer’s illness (ADVERTISEMENT), amyotrophic lateral sclerosis (ALS) and numerous system atrophy (MSA), an alpha-synucleinopathy. The Company’s exclusive target discovery engine uses a thermodynamic, computational discovery platform – ProMIS and Collective Coordinates – to anticipate unique targets referred to as Disease Specific Epitopes on the molecular surface area of misfolded proteins. Utilizing this special method, the Company is establishing unique antibody rehabs for advertisement, ALS and MSA. ProMIS has workplaces in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is noted on Nasdaq and, reliable upon the delisting, previously the TSX, under the sign PMN. Positive Statements Neither the TSX nor Nasdaq has actually examined and neither accepts duty for the adequacy or precision of this release. Specific info in this press release makes up positive declarations and positive details (jointly,”positive details”) within the significance of relevant securities laws. In many cases, however not always in all cases, positive info can be recognized by the usage
Learn more